Raymond James analyst Christopher Raymond increased his price target on Regeneron (REGN) after meeting with the company's management. After Novartis (NVS) released data on a potential competitor to Regeneron's Eylea, Raymond thinks that Novartis' drug will not be launched for at least two more years. The analyst adds that the launch of Regeneron's Duipxent drug is going well, while the company is confident that upcoming data will show that the drug effectively treats asthma. He remains upbeat on the company's outlook and thinks that the stock can continue to rise. Raymond keeps an Outperform rating on the stock.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.